Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

Labcorp launches a new FDA-approved prostate cancer test, but financial impact is unclear.

Risk flags

• ●The absence of any financial disclosure—such as pricing, projected revenue, or margin impact—creates uncertainty about the commercial significance of the assay launch. Investors cannot assess whether this product will materially affect Labcorp's financials.
• ●Forward-looking claims, such as supporting over 85% of FDA-approved drugs in 2025 and broadening access to precision medicine, are aspirational and lack supporting data. This introduces hype risk, as there is no evidence these projections will be realized.
• ●The announcement does not provide any information on market demand, competitive positioning, or payer reimbursement for the new assay. Without these details, the risk of limited adoption or commercial underperformance is elevated.

Bottom line

Labcorp's announcement of nationwide availability for Roche's VENTANA PTEN (SP218) RxDx Assay signals operational execution but lacks any disclosure of financial impact, adoption metrics, or commercial agreements. The narrative is positive and positions the company as a leader in precision diagnostics, yet the evidence is limited to company scale and disease prevalence, not business outcomes. Forward-looking statements about future FDA approvals and expanded access are unsupported by data and do not translate into actionable investment insight. For investors, this announcement is not actionable without details on revenue, profitability, or market uptake. The most important takeaway is that while Labcorp is operationally capable, the financial relevance of this assay launch remains unproven.

Announcement summary

(NYSE: LH) Labcorp announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss in tumors of patients with prostate adenocarcinoma. The assay helps identify patients who may be eligible for treatment with AstraZeneca's TRUQAP® (capivasertib) in combination with abiraterone acetate and prednisone. Prostate cancer is the most common cancer among men in the United States, with more than 330,000 new cases expected each year. Labcorp participated in Roche's early access program to support Day 1 laboratory readiness for the assay. The company's nearly 71,000 employees serve clients in approximately 100 countries, provided support for more than 85% of the new drugs and therapeutic products approved by the FDA in 2025, and performed more than 750 million tests for patients around the world. The VENTANA PTEN (SP218) RxDx Assay is now available through Labcorp's national network of laboratories. The company projects that the assay will help bring precision medicine to more patients regardless of where they receive care.

Disagree with this article?